1. Home
  2. KVUE vs NTRA Comparison

KVUE vs NTRA Comparison

Compare KVUE & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kenvue Inc.

KVUE

Kenvue Inc.

N/A

Current Price

$18.19

Market Cap

34.9B

ML Signal

N/A

Logo Natera Inc.

NTRA

Natera Inc.

N/A

Current Price

$204.76

Market Cap

32.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KVUE
NTRA
Founded
2022
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Chemicals
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.9B
32.9B
IPO Year
2023
2015

Fundamental Metrics

Financial Performance
Metric
KVUE
NTRA
Price
$18.19
$204.76
Analyst Decision
Buy
Strong Buy
Analyst Count
11
14
Target Price
$19.73
$259.07
AVG Volume (30 Days)
41.1M
1.0M
Earning Date
05-19-2026
05-19-2026
Dividend Yield
4.51%
N/A
EPS Growth
40.74
0.65
EPS
0.76
N/A
Revenue
$15,124,000,000.00
$210,939,000.00
Revenue This Year
$4.80
$16.65
Revenue Next Year
$2.52
$19.22
P/E Ratio
$24.20
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.02
$125.38
52 Week High
$25.17
$256.36

Technical Indicators

Market Signals
Indicator
KVUE
NTRA
Relative Strength Index (RSI) 47.53 44.02
Support Level $16.73 $195.46
Resistance Level $19.07 $251.09
Average True Range (ATR) 0.36 8.22
MACD -0.12 -0.20
Stochastic Oscillator 20.40 43.36

Price Performance

Historical Comparison
KVUE
NTRA

About KVUE Kenvue Inc.

Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced November 2025 that it signed a deal to be fully acquired by Kimberly-Clark with the deal expected to close during the second half of 2026.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: